Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes (DM2).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Diego
• Collaborators: National Center for Research Resources (NCRR); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Ruth L. Kirschstein National Research Service Award
• Treatments: Doxycycline

Criteria

Inclusion Criteria:

• Ambulatory, medically stable, able to give informed consent, and comply with the protocol.

• Obesity with BMI >30 kg/m2.

• DM2 for less than 10 years.

• 7.5% < HA1C < 10%

• Taking insulin and/or oral medications (biguanide, sulfonlylurea, etc.)

Exclusion Criteria:

• Mental states that would preclude complete understanding of the protocol and compliance.

• Chronic illness such as renal failure (with creatinine clearance <80 ml/min for Specific Aim 2).

• Women of child-bearing age because of the potential hazard to the fetus (doxycycline may cause permanent discoloration of the teeth and deposition in bone inhibiting growth) and because doxycycline may render oral contraceptives less effective.

• Nursing mothers.

• Allergy to tetracyclines.

• Subjects taking the following drugs: penicillin or it's derivatives, anticoagulant therapy, antacids containing aluminum, calcium, or magnesium, iron-containing preparations, bismuth subsalicylate, barbiturates, carbamazepine, phenytoin or methoxyflurane, thiazolidinediones (TZD)